Frontlight ResearchEarly access
Active, not recruitingPhase 3
Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain
Key facts
- Who runs it
- Saol Therapeutics Inc
- Where
- Altoona, Bellaire, Charleston, Charlotte, Coral Gables, Corpus Christi, Edmond, Eugene, Greenville, Greenwood Village, Orlando, Richmond, Rochester, Roseville, Salt Lake City, San Diego, Sewickley, The Villages, Tyler, Washington D.C., Winston-Salem, and Winter Park, United StatesSee the 22 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 150 people, planned
- Started
- 7 Nov 2025
- Expected to end
- 28 Feb 2027
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- SL1002
- Normal Saline
- Record updated
- 20 October 2026
Who can take part
- Age
- 40 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Male or female patients ≥ 40 years of age
- Body Mass Index (BMI) limits
- Chronic knee pain resulting from osteoarthritis
- Kellgren-Lawrence Grade 2 (mild) or Grade 3 (moderate)
- Baseline KOOS pain
- Patients taking baseline analgesics
- Diagnostic nerve block response
- Compliance with identified study requirements
Who cannot take part
- Identifiable baseline medications
- Identified alcohol or drug abuse history
- Identified underlying physiologic or psychosocial conditions
- Moderate to severe hepatic impairment
- Moderate to severe renal impairment
- Known allergies or hypersensitivity to identified agents
- Identified underlying abnormal laboratory results
- Non-OA inflammatory arthritis
- Confounding elements
- Lower limb amputation
- Specified alternate historic treatments
- Patient Health Questionnaire
- Protocol compliance requirements
- Identified underlying physical exam findings: ECG abnormalities or vital sign abnormalities during study screening per investigator assessment
Where in United States
- University Orthopedics CenterAltoona, United States
- Legent Orthopedic and Spine HospitalBellaire, United States
- Medical University of South Carolina (MUSC)Charleston, United States
- Queen City Clinical Research, PLLCCharlotte, United States
- Prime Medical ResearchCoral Gables, United States
- Institute of Precision Pain MedicineCorpus Christi, United States
- Comprehensive Specialty CareEdmond, United States
- Pacific Sports and SpineEugene, United States
- PCPMG Clinical Research Unit, LLCGreenville, United States
- DBPS Research, LLCGreenwood Village, United States
- Conquest Research, LLCOrlando, United States
- Virginia iSpine Physicians, PCRichmond, United States
- Mayo ClinicRochester, United States
- Sutter Neurology and Pain ManagementRoseville, United States
- University of Utah Orthopedic CenterSalt Lake City, United States
- Innovative Pain Treatment SolutionsSan Diego, United States
- Pain Diagnostics & Interventional Care LLCSewickley, United States
- Interventional Pain InstituteThe Villages, United States
- International Spine, Pain & Performance Center (IPP)Tyler, United States
- International Spine, Pain & Performance CenterWashington D.C., United States
- The Center for Clinical ResearchWinston-Salem, United States
- Conquest Research, LLCWinter Park, United States
About the trial
What the trial wants to find out
A Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Assess the Safety and Efficacy of SL1002 for the Treatment of Knee Pain in Patients with Osteoarthritis of the Knee.
The 2 groups in the trial
- SL1002Treatment being tested
- PlaceboPlacebo, for comparison
Normal saline
Treatment: Normal Saline
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Assess the Safety and Efficacy of SL1002 Injectable for the Treatment of Knee Pain in Patients With Osteoarthritis of the Knee
- Record updated
- 20 October 2026